Reference is made to the stock exchange announcement made on 6 June 2023
regarding Nordic Nanovector ASA's ("Nordic Nanovector") contemplated acquisition
of all the issued and outstanding shares in Thor Medical AS (the "Transaction"),
and the stock exchange announcement on 28 June regarding the approval of the
Transaction by the Company's annual general meeting. The conditions for the
consummation of the Transaction have now been fulfilled, and the Transaction has
been successfully completed. 

As a result of the Transaction, the Company has acquired 100% of the shares of
Thor Medical AS, i.e. the entire share capital on a fully diluted basis, against
issuance of 116,769,503 new shares to the former shareholders of Thor Medical
AS. Upon registration of the share capital increase pertaining to the issuance
of new shares, the Company's new share capital will be NOK 46,707,801.20 divided
by 233,539,006 shares, each of par value NOK 0.20. 

Furter, as a consequence of the Transaction, the Articles of Association of the
Company has been amended, including the change of the company name to Thor
Medical ASA, and the provision relating to the purpose of the Company. The
Company will also change its ticker to "TRMED". 

Additionally, Brede Ellingsæter has assumed the position as CFO of the Company.

Contacts

Ludvik Sandnes, chairman of the board of directors 
 +47 907 43 017

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.